Tirzepatide: Common Questions and What the Literature Says

Search traffic around tirzepatide clusters into two very different kinds of question. One kind — what the drug is, what trials measured, what adverse events appeared — has a substantial published record. The other kind — whether coffee or energy drinks interact with it, whether it causes body odor or hemorrhoids — largely does not. This page separates the two and states plainly where the literature is silent. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, symptom, or health decision.

What tirzepatide is, according to the published literature

A 2020 pharmacology paper characterised tirzepatide as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, and the researchers described the molecule as imbalanced — with relatively greater activity at the GIP receptor — and as biased at the GLP-1 receptor toward cAMP signalling over β-arrestin recruitment (PMID 32730231). That signalling profile is the mechanistic starting point for most later clinical work.

A 2023 drug monograph described tirzepatide, marketed as Mounjaro, as a once-weekly subcutaneous injection authorised for adults with type 2 diabetes as an adjunct to diet and exercise (PMID 36751934). A 2022 systematic update and a 2025 pharmacotherapy review both summarised the compound's development across glycemic and weight-related endpoints (PMID 36498958; PMID 39632534).

What the major trials measured

SURPASS-1, a double-blind randomised phase 3 trial, evaluated tirzepatide 5 mg, 10 mg and 15 mg once weekly as monotherapy in adults with type 2 diabetes; the study reported reductions in HbA1c and body weight versus placebo, with gastrointestinal events among the most frequently recorded adverse events (PMID 34186022). SURPASS-5 tested the same three weekly dose levels added to titrated insulin glargine and reported greater improvement in glycemic control and body weight than placebo over the trial period (PMID 35133415).

In obesity, SURMOUNT-4 used an open-label lead-in on a maximum tolerated dose followed by randomisation; researchers reported that participants who continued tirzepatide had further weight reduction, while those switched to placebo regained a substantial share of the weight lost (PMID 38078870). A 2025 head-to-head trial compared tirzepatide with semaglutide in adults with obesity and reported greater mean percentage weight reduction in the tirzepatide group (PMID 40353578).

Beyond weight and glucose, a 2024 trial in metabolic dysfunction-associated steatohepatitis with liver fibrosis reported that tirzepatide was more effective than placebo for resolution of steatohepatitis without worsening of fibrosis (PMID 38856224). A 2025 phase 3 trial extended testing to children and adolescents with type 2 diabetes and reported a safety profile broadly consistent with adult trials, gastrointestinal events again predominating (PMID 40975112).

Coffee and caffeine with tirzepatide: what the literature says

Among the verified papers reviewed for this page, none examined coffee, caffeine, or any caffeinated beverage as a variable. No trial in the SURPASS or SURMOUNT programs described caffeine intake as an inclusion criterion, an exclusion criterion, a covariate, or a reported interaction. There is therefore no published finding stating that coffee changes tirzepatide pharmacokinetics, alters its glycemic or weight effects, or increases the frequency of any adverse event.

What the trials did report is the adverse-event backdrop against which such questions are usually asked. In SURPASS-1 the researchers reported gastrointestinal adverse events — including nausea, diarrhea and vomiting — as the most common, and described them as generally mild to moderate and transient (PMID 34186022). The same class of events was reported in the insulin-glargine add-on trial (PMID 35133415). Whether a caffeinated drink interacts with those symptoms in any direction has not been tested in the published literature summarised here, and no inference from mechanism should be mistaken for a study result.

Energy drinks and tirzepatide: what the literature says

The same answer applies, and more strongly: no study in the verified literature evaluated energy drinks, taurine, high-dose caffeine beverages, or sugar-sweetened or artificially sweetened drinks in people receiving tirzepatide. Nothing in the trial record supports a claim that energy drinks are safe with tirzepatide, and nothing supports a claim that they are unsafe. The published record is simply silent.

One adjacent finding is worth stating precisely because it is often confused with an interaction claim. A 2023 mechanism study in adults with type 2 diabetes reported that tirzepatide reduced appetite, lowered energy intake and decreased fat mass (PMID 36857477). That finding concerns how much food and drink participants consumed and how body composition changed — it is not a statement about caffeine, and the study did not test beverage categories.

Body Odor: What Studies Report

Body odor was not reported as an adverse event in any of the verified trials or reviews covered here. The 2022 systematic update and the 2025 pharmacotherapy review, both of which summarised safety data across the development program, described gastrointestinal tolerability as the dominant safety theme rather than dermatologic or odor-related complaints (PMID 36498958; PMID 39632534). No study in this set measured sweat composition, ketone levels in relation to odor, or subjective odor reports.

This means there is no published incidence figure, no comparison against placebo, and no mechanism established in humans. Reports circulating in online communities are anecdotal; they have not been characterised in the peer-reviewed trials listed here. The accurate statement is that the question has not been studied, not that the phenomenon has been ruled out.

Hemorrhoids: What Studies Report

Hemorrhoids were not identified as a reported adverse event in the verified trials. What trials did report were bowel-habit changes in both directions: the phase 3 monotherapy trial reported diarrhea among the most common adverse events (PMID 34186022), and the pediatric phase 3 trial reported gastrointestinal events as the predominant tolerability finding in that younger population (PMID 40975112). Constipation and diarrhea are recognised within the gastrointestinal adverse-event category summarised in the review literature (PMID 36498958).

Separately, a 2024 case report described colonic ischemia in a patient receiving tirzepatide (PMID 39507503). A single case report documents an association in one person; by design it cannot establish causation, frequency, or risk in a population, and the authors presented it as a case description rather than as evidence of a defined risk. No published study in this set has examined anorectal outcomes such as hemorrhoids as an endpoint.

Gastrointestinal Adverse Events: What Studies Report

Because most lifestyle questions about tirzepatide ultimately concern gastrointestinal comfort, it is worth setting out what was actually reported. Across the phase 3 program, researchers consistently reported gastrointestinal adverse events as the most frequent category, most often nausea, diarrhea and vomiting, generally mild to moderate in severity and occurring predominantly during dose escalation (PMID 34186022). The insulin add-on trial reported a comparable pattern (PMID 35133415), as did the maintenance trial in adults with obesity (PMID 38078870). The head-to-head obesity trial likewise reported gastrointestinal adverse events in both treatment arms (PMID 40353578).

What the literature does not contain, within this verified set, is any analysis of whether diet, beverage choice, hydration pattern or caffeine intake modified those event rates. Trials recorded adverse events; they did not randomise participants to dietary co-exposures.

Reading the absence of evidence

Several of the highest-volume tirzepatide searches ask about things no one has published on. That is not unusual for a recently approved medicine: regulatory trials are powered for efficacy and broad safety signals, not for narrow lifestyle questions. Three distinctions help when reading online claims:

• Reported in a trial — the event was collected systematically and compared with a control group, as with the gastrointestinal events in the phase 3 trials (PMID 34186022).
• Described in a case report — a single patient's course, hypothesis-generating only, as with the colonic ischemia description (PMID 39507503).
• Not studied — no data either way, which is the current position for coffee, energy drinks, body odor and hemorrhoids in the literature summarised here.

Reviews are useful for the first category because they aggregate what trials collected; the 2022 systematic update and the 2025 review both function that way (PMID 36498958; PMID 39632534). They do not, however, fill gaps that the primary trials never addressed.

Regulatory context

Tirzepatide is an approved prescription medicine in several jurisdictions; the 2023 monograph described the once-weekly subcutaneous product authorised for adults with type 2 diabetes (PMID 36751934). Research-use-only material sold outside the pharmaceutical supply chain is not the same product as an approved injection and is not manufactured, labelled or tested to pharmaceutical standards. Questions about prescription status, compounding rules and product identity are decisions for licensed clinicians and pharmacists, not for online summaries.

Anyone experiencing symptoms while using a prescribed medicine — gastrointestinal or otherwise — is best served by raising them with the prescribing clinician, who can assess them in context. This page reports what studies found; it does not interpret individual symptoms.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) (Lancet, 2021)
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (JAMA, 2022)
• Tirzepatide: A Systematic Update (International Journal of Molecular Sciences, 2022)
• New Drug: Tirzepatide (Mounjaro) (The Senior Care Pharmacist, 2023)
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes (Diabetes Care, 2023)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (New England Journal of Medicine, 2024)
• Tirzepatide-Associated Colonic Ischemia (ACG Case Reports Journal, 2024)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (New England Journal of Medicine, 2025)
• Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS) (Lancet, 2025)